Triple-negative breast cancer (TNBC) is immunohistochemically negative for both the estrogen receptor (ER) and progesterone receptor (PR) and exhibits no amplification of the human epidermal growth factor receptor 2 (HER2), either [1,2]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.